Scinai Exits PC111 Deal, Shifts Focus to NanoAb Platform and CDMO Growth
Event summary
- Scinai concludes PC111 option and license arrangements with PinCell, ending on August 31, 2026.
- Company refocuses R&D resources on NanoAb platform and CDMO business to preserve capital.
- Scinai pursues €12 million grant for intradermal IL-17 psoriasis program under Poland's FENG program.
- CDMO business reports $3.1 million in committed customer orders as of August 16, 2026.
- Scinai negotiates expanded clinical manufacturing program with U.S.-based biopharmaceutical customer.
The big picture
Scinai's decision to exit the PC111 deal and refocus on its NanoAb platform and CDMO business highlights a strategic shift towards capital preservation and revenue growth. The move aligns with broader industry trends where biopharmaceutical companies prioritize scalable platforms and non-dilutive funding to enhance shareholder value. The company's focus on its CDMO business, with committed customer orders and potential expanded programs, underscores its dual strategy of therapeutic development and commercial execution.
What we're watching
- Grant Financing
- Whether Scinai secures the €12 million grant for its intradermal IL-17 program under Poland's FENG program.
- CDMO Revenue
- The pace at which Scinai converts committed customer orders into revenue and achieves its $5 million CDMO revenue target for 2026.
- Strategic Partnerships
- How Scinai leverages its NanoAb platform to pursue partnering and co-development arrangements with pharmaceutical companies.
Related topics